The 21st BioPharma Drug Discovery Nexus will be held on October 22-23, 2024, at the Holiday Inn Piscataway – Somerset, in New Jersey. New Jersey was selected as the venue for the event, as this northeastern state has been at the helm of biotech and pharma innovations and research. Experts from the region and all across the globe will grace the event and discuss challenges and opportunities in the field of drug discovery.
The event is organized by BioPharma Nexus, a trusted player in fostering connections between pharmaceutical and biotech companies, along with key service providers. Their goal is to provide the best healthcare to patients all over the globe. Service providers and businesses in biotech, pharma and healthcare, can identify and connect with partners to foster scientific and healthcare collaborations.
The event agenda:
- Automation & Computational Drug Design
- Antibody Therapeutics & Protein Engineering
- Novel Targets: Exploring Modalities in Drug Discovery
- Advancement in Cell & Gene Therapy
The 21st BioPharma Dug Discovery Nexus engages the attendees in interactive discussions, presentations and keynote speaker sessions. The speakers presiding over the keynote sessions are eminent representatives, with important insight and experience in their industry. These stalwarts from the biopharma industry will share critical information and discuss the latest trends in the industry.
New and established entities in the drug discovery spectrum can expand their connections in the pharma space. It is a phenomenal learning experience as they can get answers from top industry experts. The networking breaks offer attendees a comfortable window to connect directly with industry leaders.
To learn more, please visit https://ibn.fm/TKTOR.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN